Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities
No hay miniatura disponible
Fecha
2024-02
Profesor/a Guía
Facultad/escuela
Idioma
en
Título de la revista
ISSN de la revista
Título del volumen
Editor
Elsevier
Nombre de Curso
Licencia CC
Attribution 4.0 International
Licencia CC
Resumen
Myeloid malignancies are clonal disorders of the progenitor cells or hematopoietic stem cells, including acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative malignancies, and chronic myelomonocytic leukemia. Myeloid neoplastic cells affect the proliferation and differentiation of other hematopoietic lineages in the bone marrow and peripheral blood, leading to severe and life-threatening complications. Mesenchymal stromal cells (MSCs) residing in the bone marrow exert immunosuppressive functions by suppressing innate and adaptive immune systems, thus creating a supportive and tolerant microenvironment for myeloid malignancy progression. This review summarizes the significant features of MSCs in myeloid malignancies, including their role in regulating cell growth, cell death, and antineoplastic resistance, in addition to their immunosuppressive contributions. Understanding the implications of MSCs in myeloid malignancies could pave the path for potential use in immunotherapy.
Notas
TEXTO COMPLETO EN INGLÉS
Palabras clave
yeloid malignancies, Myeloid cells, Mesenchymal stromal cells, Cell differentiation, T-cell immunosuppression therapy
Citación
Heliyon, Volume 10, Issue 3 , 15 February 2024, e25081
DOI
https://doi.org/10.1016/j.heliyon.2024.e25081